Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
Keyword(s):
2008 ◽
Vol 27
(1)
◽
2018 ◽
Vol 27
(1)
◽
pp. 123-130
◽
Keyword(s):
2018 ◽
Vol 27
(3)
◽
pp. 771-781
◽
2012 ◽
Vol 13
(8)
◽
pp. 3747-3750
◽
Keyword(s):